Bromocriptine
A dopamine receptor agonist derived from ergot, used to treat Parkinson's disease, hyperprolactinemia, and as a unique oral medication for type 2 diabetes. In Parkinson's, it mimics dopamine to improve motor function; in diabetes, it works by resetting circadian metabolic rhythms in the brain. It can also be used to suppress lactation.
Moleküler Ağırlık
654,6000 g/mol
LogP
3,80
TPSA
118,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
InChI
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
Molecular Formula
C32H40BrN5O5
HBD / HBA
3 / 6
Döndürülebilir Bağlar
5
Ağır Atomlar
43
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A dopamine receptor agonist derived from ergot, used to treat Parkinson's disease, hyperprolactinemia, and as a unique oral medication for type 2 diabetes. In Parkinson's, it mimics dopamine to improve motor function; in diabetes, it works by resetting circadian metabolic rhythms in the brain. It can also be used to suppress lactation.
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Bromocriptine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL493. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 31101. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bromocriptine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bromocriptine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bromocriptine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bromocriptine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bromocriptine"></drugfyi-drug>